Ondansetron

Generic Name: Ondansetron

Brand Names: Zofran, Zuplenz

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₃O

CAS Number: 99614-02-5

Unique Ingredient Identifier: 4AF302ESOS

Background: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...

Indication: In the adult patient population:

i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...

Associated Conditions: Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum

Associated Therapies: -

Clinical Trials

Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron

Not Applicable

Completed

Conditions: Morphine Adverse Reaction

Interventions: Drug: Palonosetron
Drug: Ondansetron

First Posted Date: 2013-09-30

Last Posted Date: 2015-04-09

Lead Sponsor: Kyungpook National University Hospital

Target Recruit Count: 80

Registration Number: NCT01952626

Locations: 🇰🇷
Kyungpook National Hospital, Daegu, Korea, Republic of

Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients

Phase 2

Withdrawn

Conditions: Malignant Glioma

Interventions: Drug: Granisetron
Drug: Ondansetron

First Posted Date: 2013-09-30

Last Posted Date: 2014-09-22

Lead Sponsor: Duke University

Registration Number: NCT01952886

Locations: 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States

The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery

Phase 4

Completed

Conditions: Chlorzoxazone
Postoperative Pain

Interventions: Drug: Placebo
Drug: Chlorzoxazone
Drug: Morphine
Drug: Zofran

First Posted Date: 2013-09-02

Last Posted Date: 2015-09-17

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 110

Registration Number: NCT01933542

Locations: 🇩🇰
Glostrup University Hospital, Glostrup, Denmark

Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

Phase 4

Withdrawn

Conditions: Malignant Childhood Neoplasm

Interventions: Drug: Ondansetron

First Posted Date: 2013-07-11

Last Posted Date: 2013-10-08

Lead Sponsor: University of Oklahoma

Registration Number: NCT01896440

Locations: 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in EDs in Pakistan

Phase 4

Completed

Conditions: Gastroenteritis
Vomiting
Dehydration
Diarrhea

Interventions: Drug: Ondansetron
Drug: Placebo

First Posted Date: 2013-06-06

Last Posted Date: 2018-03-02

Lead Sponsor: Dr. Stephen Freedman

Target Recruit Count: 918

Registration Number: NCT01870648

Locations: 🇵🇰
Aga Khan University Hospital, Karachi, Pakistan
🇵🇰
Aga Khan Hospital for Women and Children (AKHWC), Kharadar, Karachi, Pakistan

Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan

Phase 4

Completed

Conditions: Gastroenteritis
Dehydration
Vomiting
Diarrhea

Interventions: Drug: Placebo
Drug: Ondansetron

First Posted Date: 2013-06-06

Last Posted Date: 2018-03-02

Lead Sponsor: Dr. Stephen Freedman

Target Recruit Count: 625

Registration Number: NCT01870635

Locations: 🇵🇰
Aga Khan Hospital for Women and Children (AKHWC), Kharadar, Karachi, Pakistan
🇵🇰
Aga Khan University Hospital, Karachi, Pakistan

Emergency Department (ED) Drug Interaction in Emergency Department Patients

Not Applicable

Completed

Conditions: Drug Interactions

Interventions: Drug: Ondansetron
Drug: Oxycodone
Drug: Hydrocodone

First Posted Date: 2013-05-22

Last Posted Date: 2016-05-05

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 502

Registration Number: NCT01859715

Locations: 🇺🇸
University of Colorado, Aurora, Colorado, United States

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

Phase 2

Completed

Conditions: CINV

Interventions: Drug: Ondansetron
Drug: Dexamethasone
Drug: Placebo
Drug: Fosaprepitant
Drug: APD403 IV
Drug: APD403 oral

First Posted Date: 2013-05-20

Last Posted Date: 2020-11-25

Lead Sponsor: Acacia Pharma Ltd

Target Recruit Count: 342

Registration Number: NCT01857232

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

Inhaled Ondansetron & Dyspnea

Early Phase 1

Completed

Conditions: Dyspnea

Interventions: Drug: Placebo
Drug: Ondansetron

First Posted Date: 2013-05-13

Last Posted Date: 2015-08-26

Lead Sponsor: McGill University

Target Recruit Count: 30

Registration Number: NCT01851993

Locations: 🇨🇦
Clinical Exercise & Respiratory Physiology Laboratory (CERPL) of McGill University, Montreal, Quebec, Canada

The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries

Phase 2

Completed

Conditions: Cardiac Output

Interventions: Drug: Ondansetron
Other: Normal saline

First Posted Date: 2013-04-26

Last Posted Date: 2018-05-11

Lead Sponsor: University of British Columbia

Target Recruit Count: 57

Registration Number: NCT01841606

Locations: 🇨🇦
BC Women's Hospital, Vancouver, British Columbia, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy